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Human ABCG2 is a plasma membrane glycoprotein working
as a homodimer or homo-oligomer. The protein plays an impor-
tant role in the protection/detoxification of various tissues and
may also be responsible for the multidrug-resistant phenotype
of cancer cells. In our previous study we found that the 5D3
monoclonal antibody shows a function-dependent reactivity to
an extracellular epitope of the ABCG2 transporter. In the cur-
rent experiments we have further characterized the 5D3-
ABCG2 interaction.The effect of chemical cross-linking and the
modulation of extracellular S–S bridges on the transporter
function and 5D3 reactivity of ABCG2 were investigated in
depth. We found that several protein cross-linkers greatly
increased 5D3 labeling in ABCG2 expressing HEK cells; how-
ever, there was no correlation between covalent dimer forma-
tion, the inhibition of transport activity, and the increase in 5D3
binding. Dithiothreitol treatment, which reduced the extracel-
lular S–S bridge-forming cysteines of ABCG2, had no effect on
transport function but caused a significant decrease in 5D3
binding. When analyzing ABCG2 mutants carrying Cys-to-Ala
changes in the extracellular loop, we found that the mutant
C603A (lacking the intermolecular S–S bond) showed compara-
ble transport activity and 5D3 reactivity to the wild-type
ABCG2. However, disruption of the intramolecular S–S bridge
(in C592A, C608A, or C592A/C608Amutants) in this loop abol-
ished 5D3 binding, whereas the function of the protein was pre-
served. Based on these results and ab initio folding simulations,
we propose a model for the large extracellular loop of the
ABCG2 protein.
Human ABCG2 (also called as MXR/BCRP/ABCP) is a
plasmamembrane glycoprotein that belongs to the large family
of ATP-binding cassette (ABC)3 proteins. ABCG2mediates the
energy-dependent transport of various compounds out of
the cell. The protein is abundantly expressed in the intestine,
the blood-brain barrier, and the placenta, influencing the
absorption and fetal penetration of many toxic agents and food
constituents (1). ABCG2 is also present in the liver where it is
supposed to have an important role in the excretion of toxic
metabolites into the bile (2, 3). ABCG2 is a marker protein of
stem cells (4), where its physiological role is not yet clearly
understood. It has been documented that ABCG2 expression is
up-regulated under hypoxic conditions and that the protein can
bind and/or transport porphyrins (5, 6); therefore itmay play an
important role in the protection of stem cells under hypoxic
conditions. Overexpression of ABCG2 has been demonstrated
in various tumor cells as well (1), where the transporter may be
responsible for the emergence of a multidrug-resistant tumor
phenotype that often leads to the failure of chemotherapy treat-
ment in cancer patients.
Because ABCG2 is a half-transporter, bearing only one of
each of the characteristic ABC family domains (the ATP-bind-
ing domain and transmembrane domain), ABCG2has to forma
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homodimer or homo-oligomer to become functionally active
(7, 8). The ABCG2 homodimer is covalently linked via a disul-
fide bond formed by cysteines at position 603, localized in the
large 55-amino acid-long third extracellular loop (ECL3) of
the protein (9, 10). Interestingly, mutation of Cys-603 to Ala,
Gly, or Ser does not remarkably influence the expression and
functionality of the transporter (9–11). In ECL3, ABCG2 has
two other cysteines at positions 592 and 608. These two resi-
dues are indicated as forming an intramolecular disulfide
bridge that influences plasma membrane targeting and sub-
strate specificity of the transporter (10–13).
Being a stem cell marker protein and one of the most impor-
tant ABC multidrug transporters, a sensitive method for the
detection of ABCG2 expression is of great interest. There are
severalmethods for detectingABCG2 expression in various cell
types (14); however, only a limited number of these use intact
cells, which is essential when enrichment and further culturing
of ABCG2-expressing cells (e.g. stem cells) is required. One
such example is the flow cytometric application of the 5D3
antibody, which allows the easy detection and sorting of
ABCG2-expressing intact cells.
The 5D3monoclonal antibodywas generated by immunizing
mice with murine cells expressing human ABCG2 (4). This
antibody recognizes a yet undefined, extracellular epitope of
ABCG2. Previously, we have shown that 5D3 binding strongly
depends on the conformation of ABCG2 (15). Namely, inhibi-
tion of protein function by the specific inhibitor Ko143 or by
using anABCG2 substrate flavopiridol at a high, inhibitory con-
centration, as well as ATP depletion of the cells, greatly
increases 5D3 binding, called a “5D3 shift” (15). On the other
hand, mimicking the ATP-bound state by using a non-hydro-
lyzable ATP analog, AMP-PNP, or by arresting ABCG2 by
sodium orthovanadate significantly reduces 5D3 binding (15).
We and others have also demonstrated that 5D3 can inhibit the
function of ABCG2 (15, 16). Not only is the 5D3 antibody a
good candidate for the detection of ABCG2 in flow cytometry-
based assays, but this antibody-protein interaction may also
facilitate structural studies at a molecular level, such as in the
crystallization of ABCG2. However, because 5D3 reactivity is
sensitive to conformational changes of ABCG2, proper assay
conditions must be determined and accurately controlled.
The aim of the present study was to further characterize the
conditions influencing 5D3 binding to ABCG2. We have ana-
lyzed in detail how covalent cross-linkings of two ABCG2 pro-
teins influence 5D3 binding and attempted to unravel the role
of the intra- and intermolecular disulfide bonds in 5D3 epitope
formation. We found several protein cross-linkers that signifi-
cantly increased 5D3 binding to ABCG2, resulting in a covalent
ABCG2 dimer formation and/or inhibition of transport func-
tion. However, we also found a cross-linker that caused a 5D3
shift without covalent cross-linking of the twoABCG2 proteins
or without the inhibition of ABCG2 function.Whenwe admin-
istered dithiothreitol (DTT) to intact cells to reduce extracellu-
lar cysteines, we found that this treatment abolished 5D3
binding without any effect on the transport function. Charac-
terization of 5D3 binding to ABCG2 proteins bearing muta-
tions in extracellular cysteines revealed that the intermolecular
S–S bond has only a minor effect on 5D3 binding, but disrup-
tion of the intramolecular S–S bridge has a dramatic effect on
antibody recognition. Based on these data, we suggest that the
epitope of 5D3 is located in the third, large extracellular loop of
ABCG2. Additionally, we have generated a model showing the
conformation of the third extracellular loop and revealing how
conformational changes mediated by the disruption of the
extracellular S–S bonds may influence 5D3 epitope formation.
EXPERIMENTAL PROCEDURES
Materials
Protein cross-linkers BM[PEO]3, BMPH, EDC, PMPI, sulfo-
EGS, and sulfo-MBS were purchased from Pierce. BXP-21
monoclonal antibody (3) and Ko143 (17) were kind gifts from
Drs. George Scheffer and Rik Scheper and from Dr. G. J.
Koomen, respectively.
Expression Vectors, Cell Lines, and Cell Culturing
pCIN4 bicistronic mammalian expression vectors contain-
ing the cDNAs of ABCG2-R482G, or additional Cys to Ala
mutations, were generated as described previously (10).
HEK293 cell lines expressing various ABCG2 mutants were
generated by transfection of the cells using the FuGENE 6
(Roche Applied Science). Stable cell lines were obtained by
maintaining the cells in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum, 50 units/ml penicillin,
50 units/ml streptomycin, 5 mmol/liter glutamine, and 0.5
mg/ml G418 (Invitrogen) at 37 °C in 5% CO2. To obtain a cell
line showing higher ABCG2-C592A/C608A expression, HEK-
C592A/C608A cells were sorted based on rhodamine123 extru-
sion capacity in a FACSAria flow cytometer. The sorted HEK-
C592A/C608A cell line was used throughout this study.
Generation of HEK293, A431, or PLB985 cells expressing wild-
type ABCG2 was described previously (15, 18, 19).
Generation of 5D3-Alexa647, 5D3-Fab and 5D3-Fab-Alexa647
The 5D3 monoclonal antibody was purified from the super-
natant of a hybridoma using affinity chromatography. Fab frag-
ments of the antibody were prepared by papain digestion and
separated fromFc fragments and thewhole antibody on protein
A-Sepharose column as described previously (20). Fab frag-
ments and the monoclonal antibody preparations were more
than 97% pure as determined by SDS-PAGE. The antibody and
the Fab fragments were labeled with Alexa647 succinimidyl
ester (Molecular Probes, Invitrogen) and separated from the
unconjugated dye by gel filtration on a Sephadex G-50 column
(21). The dye-to-protein labeling ratio was 3.28 and 0.98 for the
antibody and Fab preparations, respectively.
Immunodetection of ABCG2
Western Blotting—HEK cells were suspended in a Laemmli
buffer containing 2% of the reducing agent -mercaptoethanol
or without it, as indicated in Fig. 1A. Western blot analysis was
performed as described previously (22) by using the BXP-21
monoclonal antibody in a 500 dilution and a goat anti-mouse
horseradish peroxidase-conjugated secondary antibody
(5000 dilution, Jackson ImmunoResearch).
Flow Cytometry—5D3 binding in intact cells was examined
by suspending HEK cells in HPMI buffer (120 mM NaCl, 5 mM
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KCl, 400 M MgCl2, 40 M CaCl2, 10 mM HEPES, 10 mM
NaHCO3, 10 mM glucose, and 5 mM Na2HPO4) containing
0.05% bovine serum albumin (Sigma). Aliquots of the cell sus-
pension (5 105 cells in 100l) were incubatedwithAlexa647-
conjugated 5D3 antibody (2 g/ml final concentration) for 45
min at 37 °C. 5D3-Alexa647 binding was determined in a
FACSCalibur cytometer at 635 nm excitation and 661/16 nm
emission (FL4) wavelengths. When indirect labeling was per-
formed, cells were incubated with unlabeled 5D3 and mouse
IgG2b as an isotype control (both used in 1g/ml final concen-
tration) for 30 min at 37 °C. After washing, the phycoerythrin-
conjugated goat anti-mouse secondary antibody (GAM-PE,
Beckman Coulter) was used, and its fluorescence was deter-
mined at 488-nm excitation and 585/42-nm emission (FL2)
wavelengths. Labeling with 5D3-Fab was carried out the same
way as with thewhole 5D3 antibody.When labelingwas carried
out in the presence of anABCG2 inhibitor (1MKo143 or 5M
FTC), the cells were preincubated with these agents for 10 min
at 37 °C before labeling, and the inhibitors were present
throughout the antibody labeling procedure.
Confocal Microscopy
HEK cells were seeded onto 8-well Nunc Lab-Tek II cham-
bered coverglass (NalgeNunc International) at 3 104/well cell
density, and grown for 48 h in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum. For cell surface label-
ing, the cells were gently washed with Dulbecco’s modified
phosphate-buffered saline (DPBS), fixed with 1% paraformal-
dehyde in DPBS for 15 min at room temperature, and then
blocked for 1 h at room temperature in DPBS containing 0.5%
bovine serum albumin. The samples were then incubated for
1 h at room temperature with the 5D3 antibody conjugated
with allophycocyanin (R&D Systems), diluted 5 in DPBS con-
taining 0.5% bovine serum albumin, and finally washed with
DPBS.
For immunostaining of permeabilized cells, samples were
gently washed and then fixed with 4% paraformaldehyde in
DPBS for 15 min at room temperature. After a few washes with
DPBS, the cells were further fixed and permeabilized in pre-
chilled methanol for 5 min at20 °C. Following further wash-
ing steps, the cells were blocked for 1 h at room temperature in
DPBS containing 2% bovine serum albumin, 1% fish gelatin,
0.1% Triton-X 100, and 5% goat serum (blocking buffer). The
samples were then incubated for 1 h at room temperature with
BXP-21 antibody diluted 100 in blocking buffer. After wash-
ing with DPBS, the cells were incubated for 1 h at room tem-
perature with Alexa Fluor 488-conjugated goat anti-mouse IgG
(HL) (Molecular Probes) diluted 250 in blocking buffer. As
isotype controls, allophycocyanin-conjugated mouse IgG2b
(eBioscience) (5 g/ml) and mouse IgG2a (Dako) (2.5 g/ml)
plus Alexa Fluor 488-conjugated goat anti-mouse IgG (1:250)
were used. The stained samples were studied with an Olympus
FV500-IX confocal laser scanning microscope using an Olym-
pus PLAPO 60 (1.4) oil immersion objective (Olympus
Europa GmbH) at room temperature. Green and deep red flu-
orescencewas acquired above 505 and 650 nm, using excitation
at 488 and 633 nm, respectively.
Cellular Dye Uptake and Calculation of ABCG2 Transport
Activity
Formeasurement of ABCG2 activity, 5 105 HEK cells were
suspended in 100 l of HPMI buffer containing 2 M rhoda-
mine123, 5 Mmitoxantrone (MX) or 1 M pheophorbide A in
the presence or absence of 5 M FTC for 30 min at 37 °C. Cells
were thenwashed and resuspended in ice-cold phosphate-buff-
ered saline, and fluorescence was determined in a FACSCalibur
cytometer. Dead cells in the rhodamine123 uptake experiments
were excluded based on TOPRO-3 staining (Molecular Probes)
and inMX and pheophorbide A transport experiments by pro-
pidium iodide (Sigma) staining. Mean fluorescence values
measured in the absence (M0) and the presence of inhibitor
(Mi) were determined and activity was calculated as follows:
(MiM0)/Mi.
Measurement of Hoechst 33342 Transport Activity
Hoechst 33342 transport was determined as described pre-
viously (23). The effect of 5D3 (12g in 100l for 3 105 cells)
on Hoechst 33342 transport was measured as described previ-
ously (15). The effect of 5D3-Fab onHoechst 33342 uptake was
determined in the sameway, except that 24 or 48g of 5D3-Fab
was used in 100 l for 3 105 cells.
Treatment of ABCG2 with Cross-linkers or Dithiothreitol—
5  105 HEK cells were suspended in 100 l of phosphate-
buffered saline containing paraformaldehyde (PFA) (0.001–
1%), BM[PEO]3 (0.5 mM), BMPH (1mM), PMPI (1 mM), EDC (2
mM), sulfo-EGS (2 mM), sulfo-MBS (2 mM), or dithiothreitol
(1–50 mM), and incubated at 37 °C for 10 min. After washing
with 1 ml of HPMI containing 0.05% bovine serum albumin,
5D3 labeling or functional analysis of ABCG2was performed as
described above. Alternatively, cells were suspended in SDS-
sample loading buffer and analyzed by Western blotting (see
above). In some experiments PFA fixation and DTT treatment
were used in combination. In these cases, cells were fixed first
with PFA (or treated with DTT) as described above, washed
with 1 ml of HPMI, and then treated with DTT (or fixed with
PFA), washed again with 1 ml of HPMI-0.05% bovine serum
albumin, and finally labeled with 5D3.
Ab Initio Folding Simulations and Three-dimensional
Characterization of the ECL3 of ABCG2
The folding simulations of the third extracellular loop of
ABCG2 were performed as described previously (24). Briefly, a
linear ECL3 peptide (residues 563–618) was used to generate a
large, diverse pool of structures using a dynamic sampling algo-
rithm, discrete molecular dynamics (DMD) (25–28). The
search for low energy conformers was performed by replica
exchange (28, 29) DMD simulations (26–29) in two steps. In
the first round, accessible conformers of ECL3 were sampled
within a higher temperature range (0.5–0.78 /kb), and a pre-
liminary decoy set composed of structures with low potential
energy values (lower than261 ) was constructed. Then each
decoy in the preliminary set was subjected to a second round of
replica exchange DMD, with exchange temperatures in a lower
range (0.3–0.58 /kb). The final decoy set consisted of 101 low
energy structures (lower than338 ), which were relaxed in a
final step of equilibrium simulation at low temperature (0.2
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/kb). The distance between the two ends of the ECL3 was set
between 9 and 12 Å, based on existing ABC protein crystal
structures (30). The S–S distance between Cys-592 and Cys-
608 were set to maintain the disulfide bond.
To characterize the major conformations accessed by ECL3,
decoys were grouped into clusters using the k-means algo-
rithm88 (MatLab, MathWorks, Inc.) applying C root-mean-
square deviation as the similarity metric between two struc-
tures. We selected a single, representative ECL3 structure for
presentation (Fig. 8), which was obtained from the most popu-
lated cluster having the glycosylation site and cysteine 603
(responsible for intermolecular dimer interaction) on the sur-
face of the structure.
RESULTS
Effect of Paraformaldehyde Fixation on ABCG2 Protein 5D3
Antibody Interaction—5D3 is a conformation-sensitive mono-
clonal antibody that recognizes a yet undefined extracellular
epitope of the human ABC half-transporter, ABCG2. PFA gen-
erally used cross-linking fixative. Previously, we had found that
in a PLB985 cell line expressing ABCG2, PFA fixation (1% final
concentration) as well as inhibition of the function of wild-type
ABCG2, e.g. byKo143 or FTC, results in a significant increase in
5D3 labeling (5D3 shift (15)).We found that PFA also increased
5D3 binding in other ABCG2-expressing human cell lines
(A431 and HEK). When we analyzed PFA-fixed samples by
Western blotting, using the anti-ABCG2 antibody BXP-21 gen-
erated against an intracellular epitope of ABCG2, we found that
in PFA-fixed cells two higher molecular mass forms of ABCG2
appeared (Fig. 1A, lane 3). These bands have 200–250-kDa
relativemolecularweight that, despite an unusually slowmobil-
ity, has been suggested to correspond to the dimeric form of the
protein. When the ABCG2 homodimer is linked by a disulfide
bridge (8–12, 31), the covalent ABCG2 dimer can be also
detected under nonreducing conditions by Western blotting
(see Fig. 1A, lane 2).
When we analyzed HEK-ABCG2 cells not treated with any
cross-linkers but suspended in a nonreducing buffer (without
-mercaptoethanol), we found the same slower mobility bands
as in PFA-fixed samples (Fig. 1A, lane 2). These data suggest
that the higher apparent molecular mass forms observed in
PFA-treated samples aremost probably covalently cross-linked
ABCG2 dimers (see more on cross-linkers below).
To analyze whether there is a correlation between covalent
dimer formation upon PFA fixation and increased 5D3 binding,
and whether PFA cross-linking inhibits ABCG2 function, we
treated intact HEK cells expressing ABCG2 (R482G) with
increasing concentrations of PFA and analyzed 5D3 binding,
ABCG2 function, and covalent dimer formation. Throughout
this study we used both the wild-type and the R482G mutant
variant of ABCG2 in HEK cells, because the background of the
cysteine mutations was this latter variant (10). The R482G
mutant also allowed the measurement of transport activity fol-
lowed by rhodamine123 extrusion, characteristic of themutant
protein. In all functional experiments the R482G protein vari-
ant showed the same behavior regarding 5D3 binding as the
wild-type ABCG2, that is PFA or Ko143 caused a significant
5D3 shift (Fig. 1B).
When analyzing the effect of increasing amounts of PFA, we
found that 5D3 labeling showed a saturating curve. We could
already detect a slight increase in 5D3 binding at 0.05% PFA
concentration as compared with the untreated cells, and 5D3
labeling reached its maximum when cells were fixed with
0.5–1% PFA (Fig. 1C). Increased antibody binding caused by
PFA fixation was specific, as there was no 5D3 labeling in con-
trol cells transfected with an empty vector (and having no
ABCG2 expression), and the fluorescence in cells incubated
with an isotype controlmAbdid not increase uponPFA fixation
(Fig. 1C).
To examine whether fixation-mediated increase in 5D3
labeling of ABCG2 positively correlates with the inhibition of
the protein transport function, we also analyzed the effect of
PFA on the transport function of ABCG2. Fig. 1C also shows
rhodamine123 transport activity (activity factor) of the HEK-
ABCG2-R482G cells treated with increasing concentrations of
PFA.We found thatABCG2 gradually lost its activity uponPFA
fixation, but functional inactivation was observed only in cells
fixed with 0.5% or more PFA. Notably, there was already an
about 80% increase in 5D3 labeling in the 0.1% PFA-fixed sam-
ples, whereas rhodamine123 extrusion was hardly inhibited
(less than 20%) at this PFA concentration. When we analyzed
PFA-fixed cells byWestern blotting (Fig. 1D), we found that the
relative amount of covalently linked ABCG2 dimer greatly
increased in cells fixed with 0.5% or more PFA; thus, covalent
cross-linking seemed to correlate with the inhibited transport
function but not with the 5D3 shift.
Effect of Various Protein Cross-linkers onABCG2Protein 5D3
Antibody Interaction—To further investigate whether there is a
correlation between covalent cross-linking of the ABCG2
monomers and an increased 5D3 binding, we treated ABCG2
expressing cells with different specific protein cross-linkers and
analyzed them for 5D3 binding, functionality and dimer forma-
tion. We chose several non-cell-permeable protein cross-link-
ers, reacting with different amino acid side chains on the cell
surface (Table 1). As Fig. 2 shows, we found several protein
cross-linkers (BM[PEO]3, BMPH, sulfo-MBS, and PMPI) that
increased 5D3 binding up to the level observed in FTC or PFA
treated cells, whereas they did not affect the labeling of control
cells or the fluorescence measured with the isotype antibody
control (not shown).
To examine whether the observed increase in 5D3 binding in
these protein cross-linker treated samples was due to the inhi-
bition of the function of ABCG2, we analyzed rhodamine123
uptake in these cells (Fig. 2A, right panel). We found that EDC,
sulfo-EGS, sulfo-MBS, and PMPI did not inhibit the transport
function of ABCG2, whereas the others abolished rhoda-
mine123 extrusion. We also analyzed protein cross-linker
treated cells for covalent ABCG2 dimer formation by Western
blotting and found that BMPH and EDC, two compounds that
caused a 5D3 shift, did not result in a covalently linked ABCG2
(Fig. 2B). The experiments shown in Fig. 2 were performed in
HEK-ABCG2-R482G cells, but experiments repeated in both
PLB985 and A431 cells, expressing the wild-type ABCG2 pro-
tein, provided the same results (data not shown).
In summary, we found that the effect of cross-linkers was
highly variable as to function, 5D3 labeling, and covalent dimer
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formation (see Table 1). These results suggest that covalent
cross-linking of two (ormore) ABCG2s is neither sufficient nor
necessary for an increased 5D3 binding and/or for transport
inhibition. From these data it seems likely that fixation of the
epitope on a monomeric ABCG2 protein, even without the
inhibition of transport function, may be responsible for an
increased 5D3 binding.
Effect of DTT Treatment on 5D3 Binding—ABCG2 has three
cysteines localized on the cell surface in the large third extra-
cellular loop of the protein. It has been suggested that Cys-603
is responsible for intermolecular S–S bond formation, whereas
the other two cysteines, Cys-592 and Cys-608, form an
intramolecular S–S bridge (9–12). To find out whether the
extracellular S–S bonds formed by cysteines are important for
5D3 recognition, we treated HEK-ABCG2 cells with the reduc-
ing agent DTT, which has a slow or insignificant cellular per-
meation. We found that treatment with 10 mM DTT caused a
significant decrease in 5D3 binding in native (nonfixed) cells;
FIGURE 1. A, effect of PFA fixation on covalent ABCG2 dimer formation. HEK-ABCG2-R482G cells were lysed, dissolved in disaggregation buffer containing the
reducing agent-mercaptoethanol or without it (as indicated on the figure), and subjected to 7.5% SDS-PAGE. ABCG2 in cells fixedwith 0.5% PFA prior to cell
lysis is also shown. 15g of proteinwas loaded into each lane. ABCG2was detected by the BXP-21 antibody. B, effect of PFA fixation on 5D3 labeling of ABCG2.
HEK293 cells transfected with empty pCIN4 or pCIN4-ABCG2(R482G) were labeled with Alexa647-conjugated 5D3. Fluorescence was detected using a
FACSCalibur cytometer. The solid line represents 5D3 binding of 0.5% PFA-treated and the dotted line for nontreated (native) cells. The dashed line represents
labeling of cells in the presence of the specific ABCG2 inhibitor, Ko143. C, 5D3 labeling and activity of ABCG2 in cells treatedwith increasing concentrations of
PFA. Mock or pCIN4-ABCG2(R482G)-transfected HEK293 cells were fixed with increasing concentrations of PFA, washed, and then labeled with 5D3 antibody
or mouse IgG2b (isotype control (IT)). Fluorescence of goat anti-mouse phycoerythrin-conjugated secondary antibody was detected in a FACSCalibur cytom-
eter. Fluorescence values are shown as the percentage of maximum labeling obtained in ABCG2-expressing cells fixed with 1% PFA and labeled with 5D3.
Rhodamine123 uptake is shown in the presence of increasing concentrations of PFA. HEK-ABCG2 cells were fixed with increasing concentrations of PFA,
washed, and then incubated with 2 M rhodamine123 or 2 M rhodamine123  1 M Ko143. Rhodamine123 fluorescence in living cells was detected in a
FACSCalibur cytometer. Rhodamine123 extrusion activity of ABCG2 is shown as the percentage of maximum activity. Activities were calculated as follows: (Mi 
M0)/MiwhereMi is themean rhodamine123 fluorescence in thepresenceofKo143andM0 is themean fluorescencewithoutKo143. Shown is theaverageof two
independent experiments. D, Western blot analysis of ABCG2 in HEK cells treated with increasing concentrations of PFA. HEK-ABCG2 cells were fixed with
increasing concentrations of PFA or without it (first lane), washed, and then suspended in disaggregation buffer. Samples (each containing 15 g of protein)
were then subjected to 7.5% Laemmli gel electrophoresis and electroblotting. ABCG2 was visualized by the BXP-21 antibody.
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this low 5D3 binding persisted even if the cells were fixed by
PFA after the DTT treatment (Fig. 3B). DTT treatment had no
effect on the negligible 5D3 labeling of HEK cells transfected
with the empty vector (Fig. 3A), nor did it affect the fluores-
cence of HEK-ABCG2 cells incubated with an isotype control
antibody. In parallel experiments we analyzed the effect of DTT
on the function of ABCG2 and found that even in cells treated
with 10–50mMDTT,ABCG2was fully active (data not shown).
This latter finding is in harmony with the results of Mitomo et
al. (31), who demonstrated that -mercaptoethanol, another
reducing agent, does not influence the functionality of ABCG2.
We also examined the expression level and dimerization of
ABCG2 in DTT-treated samples by Western blotting. We
found that 10 mMDTT treatment resulted in the complete loss
of ABCG2 dimer formation observed in samples dissolved in
loading buffer without the reducing agent -mercaptoethanol.
However, DTT had no effect on the covalent cross-linking of
ABCG2s by PFA (not shown). These results suggested that
intact S–S bridges in theABCG2protein on the cell surfacemay
play an important role in the 5D3 epitope formation.
Expression, Function, and 5D3 Binding of ABCG2 Variants
Carrying Cys-to-Ala Mutations in the Third Extracellular
Loop—To investigate whether DTT treatment causes a
decrease in 5D3 binding due to the reduction of the intramo-
lecular or intermolecular S–S bonds, or which of these bonds
are important for 5D3 epitope formation, we expressedABCG2
mutants having single Cys-to-Ala changes or the combination
of these mutations in HEK cells.
Fig. 4A shows that all Cys-to-Alamutants (except forC603A/
C608A that was expressed in very low amount and exclusively
in an underglycosylated form) could be detected by Western
blotting, using the ABCG2-specific BXP-21 antibody. The
mutants C592A and C603A showed expression levels compa-
rable to that of the wild-type ABCG2, whereas the amount of
doublemutant C592A/C608A or the triple Alamutant proteins
was about 50% of that seen for the wild-type ABCG2.
To analyze whether the ABCG2 cysteinemutants were func-
tional, we performed fluorescent dye uptake experiments by
flow cytometry and fluorometry (Fig. 4B). We analyzed the
transport of four different fluorescent ABCG2 substrate com-
pounds, MX, pheophorbide A, Hoechst 33342, and rhoda-
mine123 (rhodamine123 is transported only by the R482G
ABCG2 mutant). We found that all of the expressed cysteine
mutants were functional, bearing dye extrusion capacity, but
there was a significant variation in their transport activities rel-
ative to the different transported compounds.
Hoechst 33342 and pheophorbide A were transported by all
of themutants (except for C603A/C608A); however, themitox-
antrone transport capacity of themutants, lacking the intramo-
lecular or both disulfide bonds, was significantly weaker than
that of the R482G or C603A variants. There was also a differ-
ence in rhodamine123 uptake, with the C592A and C592A/
C603A mutants showing practically no transport activity (Fig.
4B). These data are in harmony with the findings of Henriksen
et al. (10), who report that some of theCys-to-Alamutants have
altered substrate specificity.
When cells expressing the differentCys-to-Alamutantswere
labeled with the 5D3 antibody, we found that only the C603A
variant had a clearly detectable 5D3 labeling and the C592A/
C608A mutant showed some weak 5D3 binding capacity (Fig.
5A, upper panel). Similar to that seen in the case of the wild-
type ABCG2, PFA fixation (Fig. 5A, lower panel) or Ko143
treatment (not shown) of the cells expressing the C603A
mutant and the double mutant C592A/C608A resulted in an
increased 5D3 binding. However, the othermutant variants did
not show any labeling, even in PFA-fixed or Ko143-inhibited
samples.
To rule out the possibility that lowprotein expression level or
protein dislocalization was responsible for the absence of label-
ing ofmost of themutants, and to test whether they could reach
the plasma membrane (necessary for recognition by 5D3 anti-
body), we analyzed ABCG2 immunofluorescence by confocal
microscopy.
Fig. 5B shows that all mutants could be detected by the
BXP-21 antibody, recognizing an intracellular epitope of
ABCG2, and all of them were present in the plasma membrane
(except for the hardly expressedC603A/C608A doublemutant,
which was found, for the most part, intracellularly). However,
5D3 labeling analyzed by confocal microscopy gave the same
result as the flow cytometry measurements, that is, only the
cells expressing the wild-type ABCG2, C603A, and the C592A/
C608A variants (the latter one seen only at increased detector
voltage) could bind the 5D3 antibody.
It has been shown that the 5D3 antibody inhibits the trans-
port function ofABCG2 (as judged in a sensitiveHoechst 33342
assay), although this inhibition is only partial and requires high
concentrations of the antibody (15). To analyze a potential cor-
relation between 5D3 binding and transport inhibition, we
added high concentrations of 5D3 to the HEK cells and then
analyzed ABCG2-specific Hoechst 33342 transport activity.
We found that, in contrast to a 30–40% inhibition found in the
case of the wild-type ABCG2, 5D3 did not influence the
Hoechst 33342 transport activity of the C592A/C608A and
C592A/C603A/C608A mutants (data not shown). All of these
data strongly suggest that the ABCG2 mutant proteins lacking
the cysteines required for intramolecular S–S bridge forma-
TABLE 1
Effects of protein cross-linkers on 5D3 binding, transport activity, and covalent dimer formation of ABCG2
Cross-linker Side chainscross-linked
Spacer arm
length
Increased
5D3 binding
Inhibition of
transport function
Cross-linked ABCG2
onWestern blot
Å
BMPEO3 SH2–H2 14.7 Yes Yes Yes
BMPH CH3–SH2 8.1 Yes Yes No
EDC COOH–NH2 0 Yes No No
Sulfo-EGS NH2–NH2 16.1 No No Yes
Sulfo-MBS NH2–SH2 9.9 Yes No Yes
PMPI SH2–OH 8.7 Yes No Yes
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tion are expressed in comparable amounts, reach the cell sur-
face, and work as active transporters in a manner similar to the
wild-type ABCG2, but these variants (except for the C592A/
C608A mutant showing weak 5D3 binding) are unable to bind
the 5D3 antibody.
Effect ofDTTon5D3Labeling of theCys-to-AlaMutants—To
test whether decreased 5D3 binding inABCG2-expressing cells
treated with DTT was due to the reduction of the extracellular
cysteines, we also examined the effect of DTT on 5D3 labeling
of the mutants C603A and C592A/C608A in native or PFA-
fixed cells. Fig. 6,A andB, shows thatDTT is still effective in the
reduction of 5D3 binding in the case of the C603A mutant but
has practically no effect on 5D3 labeling of the C592A/C608A
mutant. When we analyzed 5D3 fluorescence in ABCG2-ex-
pressing HEK cells treated with increasing concentrations of
DTT, we found that DTT treatment caused a gradual decrease
FIGURE 2.A, effect of protein cross-linkers on 5D3 labeling and function of ABCG2. HEK-ABCG2-R482G cells were incubatedwith different protein cross-linkers,
washed, and then labeledwith 5D3-Alexa647 (left panel) or incubatedwith 2M rhodamine123 (right panel) in the presence or absence of the inhibitor Ko143.
Fluorescence was determined by flow cytometry. Left panel, dotted lines represent labeling of mock-transfected native cells, and dashed lines stand for
mock-transfected cells treatedwith cross-linker (or FTC). The solid lines represent 5D3 labeling of native, and heavy solid lines show cross-linker (or FTC)-treated
ABCG2-expressing cells. Right panel, rhodamine123 uptake of cross-linker (or FTC) nontreated HEK-ABCG2 cells (solid line) or cross-linker (or FTC)-treated
HEK-ABCG2 cells (heavy solid line). Only living cells are shown in the right panel. B, Western blot analysis of the effect of protein cross-linkers on ABCG2.
HEK-ABCG2 cells were incubated with different protein cross-linkers, washed, and then suspended in Laemmli buffer. Proteins were separated by 7.5%
SDS-PAGE.After electroblotting,ABCG2wasdetectedbyusing theBXP-21antibody. Each lane represents 15gofprotein (/0, in the caseof PFA, its inhibitory
effect depends on the concentration used; see Fig. 1C). sEGS, sulfo-EGS; sMBS, sulfo-MBS.
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in 5D3 binding that reached its minimum (almost the fluores-
cence of the background) at 10–50 mM DTT in ABCG2 and
C603A-expressing cells, whereas DTThad no effect on labeling
of the C592A/C608A double mutant (Fig. 6C). These experi-
ments suggest that the intramolecular and not the intermolec-
ular S–S bonds are important in 5D3 epitope formation.
Experiments with 5D3-Fab—To analyze whether the 5D3
shift is caused by the stabilization of the epitopes in a dimer
form of ABCG2, and thus an intact, bivalent 5D3 is required for
labeling, we incubated HEK-ABCG2 cells with the Alexa647-
conjugated Fab fragment of 5D3.We found a lower affinity but
specific binding of 5D3 Fab to ABCG2 that was greatly
increased by PFA fixation or by Ko143. DTT treatment also
reduced Fab binding (Fig. 7). These experiments also suggest
that 5D3 binding toABCG2depends on the conformation of an
epitope found on a monomeric ABCG2.
DISCUSSION
ABCG2 is a marker protein of the side population of stem
cells and is also important in tumor cells where it can mediate
the emergence of a multidrug-resistant phenotype. On one
hand, a sensitive method for the detection of low amounts of
ABCG2 may allow the enrichment and selection of ABCG2-
expressing cells, such as stem cells. On the other hand, moni-
toring the presence of ABCG2 in tumor samples from patients
can help to find the most effective chemotherapy treatment
using non-ABCG2 substrate drugs. The conformation-sensi-
tive antibody 5D3 is a good candidate for the detection of
ABCG2 for the above mentioned purposes. However, to estab-
lish a reliable method it is essential to find the optimum condi-
tions to be able to detect even low amounts of endogenous
ABCG2. In our previous paper we showed that 5D3 binding
depends on the actual conformation of ABCG2 (15). We could
define two ABCG2 conformations based on the 5D3 binding
capacity. The high affinity form was observed in ABCG2 inhib-
ited by the specific inhibitor Ko143 in ATP-depleted cells or
after fixation of the cells with PFA, whereas stabilization of
ABCG2 in a vanadate-trapped form resulted in decreased 5D3
binding, representing a low affinity form.
In this study we have further analyzed how alterations in
ABCG2 structure, covalent cross-linking, or changes in the S–S
FIGURE3.EffectofDTTtreatmenton5D3binding.HEK293cells transfected
with empty pCIN4 (A) or pCIN4-ABCG2(R482G) (B) were incubated with or
without 10mMDTT, washed, and then labeled with 5D3 ormouse IgG2b and
goat anti-mouse phycoerythrin-conjugated secondary antibody. The upper
panels represent labeling of PFA nontreated cells (native), and the lower pan-
els show labeling of cells that were fixed with 1% PFA after DTT treatment.
Dotted lines, isotype control; dot-dash-dotted lines, isotype control of DTT-
treated cells; solid lines, 5D3; dashed lines, 5D3 labeling of DTT-treated cells.
FIGURE 4. A, expression of various ABCG2 mutants carrying Cys-to-Ala changes. HEK cells were transfected with pCIN4 vectors encoding different Cys-to-Ala
ABCG2mutants or R482G (indicated as ABCG2). Cells were lysed, dissolved in disaggregation buffer, and subjected to 7.5%SDS-PAGE. ABCG2was detected by
the BXP-21 antibody. To demonstrate differences in the expression level of themutants, various amounts of samples were loaded onto the gel as indicated in
the figure.B,mitoxantrone, pheophorbideA, rhodamine123, andHoechst 33342 transport activity of Cys-to-Alamutants. HEK cells expressingdifferentABCG2
mutants or R482G (indicated as ABCG2) were incubated with 5 M mitoxantrone, 1 M pheophorbide A, 2 M rhodamine123, or 1 M Hoechst 33342 in the
absenceor presenceof 1MKo143. Fluorescenceofmitoxantrone, pheophorbideA, and rhodamine123wasdetected in a FACSCalibur cytometer, and activity
factors were calculated frommean fluorescence values as described under “Experimental Procedures.” Fluorescence due to Hoechst 33342 accumulationwas
determined in a spectrofluorimeter. The transport rate was determined as described under “Experimental Procedures.” Shown are the average transport
activities obtained from two independent experiments.
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bonds on the external regions of ABCG2 influence 5D3 bind-
ing.When analyzing the effects of PFA fixation inHEK-ABCG2
cells, we found that although at higher concentrations PFA
abolishes ABCG2 function and results in the formation of an
ABCG2 dimer, at lower concentrations, which already cause a
5D3 shift, PFA is neither inhibitory on function nor does it
cross-link ABCG2 dimers (Fig. 1, C and D). When we analyzed
the effects of specific protein cross-linkers on 5D3 binding to
ABCG2, we found that some of these agents increased 5D3
binding while causing a variable loss in transport function or
covalent dimer formation.
In fact, EDC resulted in a 5D3 shift without the inhibition of
ABCG2 function or covalent formation of an ABCG2 dimer
(see Fig. 2, A and B). Thus, there was no general correlation
between the 5D3 shift and the inhibition of the function or
cross-linking of ABCG2 dimers. Experiments performed with
the Fab fragment of 5D3 (see Fig. 7), having only one binding
region, also suggested that the epitope is most probably located
on an ABCG2 monomer.
The ABCG2 homodimer is linked via a disulfide bond medi-
ated by Cys-603, found in the third extracellular loop of the
protein. Additionally, there are two other cysteines (Cys-592
and Cys-608) in the third extracellular loop of ABCG2, sug-
gested to form an intramolecular S–S bridge. When we treated
intact HEK-ABCG2 cells with the nonpermeable reducing
agentDTT,we found a significant decrease in 5D3 bindingwith
no effect on the ABCG2 transport function (see Figs. 3 and 6),
indicating a dramatic effect of the disruption of the extracellu-
lar S–S bonds on the 5D3 epitope formation. To find out which
disulfide bridge is important for epitope formation,we analyzed
different Cys-to-Ala mutants lacking the intermolecular
(C603A), the intramolecular (C592A, C608A, C592A/C608A),
or both kinds of (C592A/C603A, C603A/C608A, or C592A/
C603A/C608A) S–S bonds.
We found that the C603A mutant behaves similarly to
ABCG2 having intact S–S bridges. The C603A mutant, which
can be expressed in an amount comparable to ABCG2, is found
in the plasmamembrane (Figs. 4A and 5B). This mutant is fully
FIGURE 5.A, 5D3 labeling ofHEK cells expressingdifferent Cys-to-Alamutants of ABCG2. Native (upper panel) or 1%PFA-treated (lower panel) cellswere labeled
with 5D3-Alexa647. 5D3 fluorescence was detected by flow cytometry. Then solid lines represent 5D3-Alexa647 labeling of cells expressing different ABCG2
mutants, as indicatedabove thepanels, and thedotted lines represent 5D3-Alexa647 labelingof cells transfectedwithemptyvector.B, localizationof theABCG2
Cys-to-Ala mutants. HEK cells expressing different ABCG2 mutants (as indicated above the panels) were fixed in 4% paraformaldehyde, permeabilized in
prechilled methanol, and then incubated with the BXP-21 antibody and Alexa Fluor 488-conjugated goat anti-mouse IgG. To label the cell surface epitope of
ABCG2, a direct immunofluorescent reaction was performed. The cells were fixed with 1% paraformaldehyde and then incubated with allophycocyanin-
conjugated 5D3. The stained slideswere analyzed using anOlympus FV500-IX confocal laser scanningmicroscope. Fluorescencewas acquired using the same
equipment settings, except the slide representing 5D3 labeling of C592A/C608A was taken at an increased detector voltage.
Interaction of ABCG2with the 5D3Monoclonal Antibody
SEPTEMBER 19, 2008•VOLUME 283•NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 26067
 by guest, on April 6, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
active and has the same substrate
specificity as ABCG2 (Fig. 4B).
Cys-603 has a clearly detectable
5D3 binding that can be increased
by inhibition of ABCG2 function
by Ko143 or treatment with pro-
tein cross-linkers. DTT treatment
also decreased 5D3 binding of this
mutant (Fig. 6), suggesting that
this cysteine is not important for
the observed effect of S–S bridge
reduction.
The single mutants, lacking the
intramolecular S–S bond, i.e.
C592A, C608A, as well as the
C592A/C603A/C608A variant, had
clearly detectable expression levels,
were present in the plasma mem-
brane, and were functional for
active transport with somewhat
altered substrate specificities (Figs.
4 and 5). However, these mutants
did not show any specific 5D3 bind-
ing either in a PFA-fixed or in a
Ko143-inhibited form, and more-
over, 5D3 did not inhibit their func-
tion. These experiments suggest
that the intramolecular S–S bridge
in the third extracellular loop of
ABCG2 has a crucial, either direct
or indirect (e.g. stabilizing the
proper conformation), role in the
formation of the 5D3 epitope as well
as in the substrate specificity of the
transporter.
The role of the intramolecular
S–S bond in 5D3 epitope formation
has already been suggested (9, 10).
Kage et al. (9) analyzed 5D3 labeling
in intact cells expressing various
Cys-to-Ser mutants by flow cytom-
etry. They found that C592S and
C608S had impaired 5D3 binding;
however, these twomutants showed
very low expression levels in this
study (9). In our experiments we
were able to express C592A and
C608A mutants in comparable lev-
els to the wild-type ABCG2. More-
over, we demonstrated that even
though these mutants were func-
tional and properly localized to the
plasma membrane, they could not
be labeled with 5D3 even in the
presence of an inhibitor or PFA.
Henriksen et al. (10) also sug-
gested the role of the intramolecular
S–S bridge of ABCG2 in 5D3 bind-
FIGURE 6. A and B, effect of DTT on labeling of the Cys-to-Ala mutants. HEK293 cells expressing different ABCG2
mutants were treated with 10 mM DTT, washed, and then labeled with 5D3-Alexa647 (A). B shows the labeling of
samples fixedwith 0.5%PFAprior to antibody labeling. Fluorescencewas determined in a FACSCalibur cytometer.
Dotted lines, mock-transfected HEK; dot-dash-dotted lines, DTT-treated, mock-transfected HEK cells; solid lines, HEK
cells expressing different ABCG2mutants; dashed lines, HEK cells expressing different ABCG2mutants treatedwith
DTT.C,HEKcellsexpressingdifferentABCG2mutantswere treatedwith increasingconcentrationsofDTT, fixedwith
0. 5% PFA, and labeled with 5D3-Alexa647. 5D3 fluorescence was determined by flow cytometry. Mean values
obtained from at least in two independent experiments are shown.
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ing; they detected no 5D3 labeling by confocal microscopy for
C592A, C608A, and the C592A/C608A double mutant. In har-
mony with this study, we could not detect any labeling for the
single Cys-to-Ala mutants. However, in our hands the C592A/
C608A doublemutant showed a weak 5D3 binding both in flow
cytometry and confocal microscopy, and the 5D3 shift upon
PFA or Ko143 treatment could also be observed (Fig. 5). DTT
had no effect on the 5D3 labeling of the C592A/C608A variant
(Fig. 6), and the excess amount of 5D3 did not inhibit the func-
tion of this mutant.
The single Cys-592 or Cys-608mutants showed an increased
cytoplasmic accumulation (9, 10, 13), whereas the simultane-
ous removal of cysteines 592 and 608promotedprotein stability
and proper targeting (10). Thus such a double mutation may
allow the development of a favorable conformation within the
ABCG2 protein, allowing some 5D3 labeling.
Based on these data we suggest that protein cross-linking
most probably stabilizes the epitope of 5D3 present within a
single ABCG2 protein. The effect of DTT treatment on 5D3
labeling together with experiments on the extracellular Cys-to-
Alamutants revealed that the third extracellular loop, and espe-
cially the intramolecular S–S bond within this region, has a
crucial role in 5D3 epitope formation and probably in the sub-
strate interactions of ABCG2.
To visualize the possible molecular arrangement of the third
extracellular loop (ECL3) of the ABCG2 protein, we performed
a molecular dynamic simulation of the folding of this relatively
large protein sequence. Currently, there are no atomic struc-
tures available for eukaryotic ABC transporters, and molecular
modeling is usually guided by the recently solved structures of
bacterial transporters. Although a recent communication
offers a homology model for ABCG2 (30), it does not include
ECL3, as this loop shows no homology to any ABC protein
sequences with a known structure. Data for other ABC trans-
porters, however, suggest that the adjacent transmembrane
regions of these proteins are found near each other, within a
distance of 9–12 Å. Therefore in our simulation algorithm, we
fixed theN- andC-terminal regions of the ECL3 at this distance
at the membrane surface. We have also included the informa-
tion that the cysteines forming intramolecular S–S bonds (Cys-
592 and Cys-608), as well as a cysteine involved in the intermo-
lecular S–S bridge formation, are most probably located on the
surface of this loop. It is interesting to note, that many of the
ABCG-type proteins have this large, conserved, extracellular
region, with similar arrangements of cysteines and potential
glycosylation sites (11).
The conformation obtained, as seen in Fig. 8, corresponds to
these requirements and suggests the presence of a stabilized
antiparallel loop with -sheets in the region of the three cys-
teines, surrounding the glycosylation site.When eitherCys-592
or Cys-608 was replaced by alanines in the in silico model, the
structure of the antiparallel loop collapsed and the folding lost
its conserved characteristics (data not shown). The combina-
tion of the experimental and the simulation results suggest a
well defined structure in this area of ECL3, which may be
important in mediating ABCG2 interaction with the plasma
membrane or other proteins. Moreover, the conformation of
this loop seems tomodulate the substrate and antibody binding
to this membrane transporter.
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